Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 09, 2025 12:24 ET | Source: Intermountain Health

Intermountain Health Research: Targeted Vitamin D3 Supplementation Cuts Risk of Heart Attack Patients Having a Second Heart Attack in Half

NEW ORLEANS, Nov. 09, 2025 (GLOBE NEWSWIRE) -- A tailored approach of vitamin D3 supplementation in patients who have suffered a heart attack significantly reduces their risk of a second heart...
November 09, 2025 10:15 ET | Source: George Medicines

George Medicines presents long-term efficacy and safety data for single pill triple combination therapy for hypertension at American Heart Association’s Scientific Sessions 2025

London, UK, Boston, MA, 9 November 2025 – George Medicines, a late-stage biopharmaceutical company focused on addressing significant unmet needs in cardiometabolic disease, today presented long-term...
November 06, 2025 12:00 ET | Source: Elixir Medical Corporation

Elixir Medical Highlights Results From “Real World” MY-IVL Study Demonstrating Performance of LithiX™ Hertz Contact (HC) Intravascular Lithotripsy System (IVL) in Treating Calcified Coronary Lesions

LithiX™ HC-IVL is a novel lithotripsy system designed to facilitate treatment of heart disease exacerbated by the presence of calcium within coronary artery plaques MY-IVL study enrolled 102 real...
October 31, 2025 07:30 ET | Source: Cytokinetics, Incorporated

Cytokinetics Announces Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced upcoming presentations, including three Late Breaking Science presentations...
October 29, 2025 14:00 ET | Source: Circle Cardiovascular Imaging Inc.

Circle CVI Announces FDA Clearance for cvi42 | Plaque for Coronary Artery Disease Evaluation

Circle CVI has received FDA 510(k) clearance for cvi42 | Plaque, its AI-enabled coronary plaque analysis solution.
October 29, 2025 05:00 ET | Source: Royal Philips

Late-breaking iMODERN findings presented at TCT 2025 and published in the New England Journal of Medicine highlight new evidence to guide treatment choices for heart attack patients

October 29, 2025 3-Year data from the largest global trial to date using Class I, Level A iFR in heart attack patients shows treating additional stenoses in the same procedure showed no significant...
October 27, 2025 17:00 ET | Source: Elixir Medical Corporation

Elixir Medical annonce de nouveaux résultats cliniques significatifs pour le DynamX® Bioadaptor, démontrant une réduction de près de 50 % des taux d’événements coronariens par rapport à la norme actuelle de soins ICP

Les résultats ont été présentés lors de la Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 à San Francisco, le 27 octobre 2025 Le DynamX® Bioadaptor est la première technologie...
October 27, 2025 17:00 ET | Source: Elixir Medical Corporation

Elixir Medical anuncia resultados clínicos recientes y significativos sobre el Bioadaptador DynamX® que demuestran una reducción de casi el 50 % en las tasas de acontecimiento coronarios en comparación con el tratamiento de referencia actua

Los resultados se presentaron en el congreso Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 en San Francisco (EE. UU.) el 27 de octubre de 2025 El Bioadaptador DynamX® es la primera...
October 27, 2025 17:00 ET | Source: Elixir Medical Corporation

Elixir Medical gibt klinische Late-Breaking-Ergebnisse für DynamX® Bioadaptor bekannt, die eine signifikante Reduzierung von koronaren Ereignisraten um nahezu 50 % gegenüber dem aktuellen PCI-Behandlungsstandard zeigen

Die Ergebnisse wurden bei der Transcatheter Cardiovascular Therapeutics (TCT)-Konferenz 2025 in San Francisco am 27. Oktober 2025 vorgestellt. Der DynamX® Bioadaptor ist die erste interventionelle...
October 27, 2025 17:00 ET | Source: Elixir Medical Corporation

Elixir Medical Announces Significant Late Breaking Clinical Results for DynamX® Bioadaptor Demonstrating Nearly 50% Reduction in Coronary Event Rates vs. Current PCI Standard of Care

Results were presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 in San Francisco on October 27, 2025 DynamX® bioadaptor is the first interventional technology to...